Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04362566 · ClinicalTrials.gov registry record · Phase 4
Bupivacaine for Post-operative Pain in Mohs
A Phase 4 study, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- Phase 4
- Development phase
- 174
- Enrollment target
NCT04362566 is a Phase 4 study that has completed, run by University of Missouri-Columbia. The registered enrollment target is 174 participants.
The verdict
NCT04362566, a Phase 4 study, has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 174 participants
- Enrollment target
Study Summary
Mohs micrographic surgery (MMS) is regarded as the gold standard for the treatment of high-risk nonmelanoma skin cancer (NMSC). Pain after MMS peaks on the day of surgery and slowly decreases thereafter. The most common post-operative analgesics include acetaminophen, ibuprofen and narcotics. Lidocaine is the most commonly used anesthetic in MMS, but bupivacaine has been shown in other surgical specialties to be an effective adjuvant to reduce post-operative pain and opioid use when injected locally in the immediate postoperative period. Bupivacaine has also been shown to reduce intra-operative pain during MMS. The investigators plan a single-blinded prospective, randomized, controlled trial to determine if post-operative wound infiltration of bupivacaine versus normal saline improves post-operative pain and decreases need for post-operative pain medications including both narcotic and nonnarcotic analgesics.
Interventions
- DRUG Bupivacaine
- OTHER Placebo Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04362566
The ClinicalTrials.gov registry entry for NCT04362566 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT04362566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04362566 about?
NCT04362566 is a clinical study titled "Bupivacaine for Post-operative Pain in Mohs". Mohs micrographic surgery (MMS) is regarded as the gold standard for the treatment of high-risk nonmelanoma skin cancer (NMSC). Pain after MMS peaks on the day of surgery and slowly decreases thereafter. The most common post-operative analgesics include acetaminophen, ibuprofen and narcotics. Lidoca...
What is the current status of trial NCT04362566?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 174 participants. The study started on 2020-07-30. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT04362566?
The interventions under investigation include: Bupivacaine (DRUG), Placebo Saline (OTHER).
Who is sponsoring clinical trial NCT04362566?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.